Gore Reaches Target Enrollment for GREAT Registry

November 15, 2016–Gore & Associates, Inc. announced today at the VEITHsymposium in New York, NY, that they have reached their target enrollment for the Global Registry for Endovascular Aortic Treatment (GREAT). According to Gore, more than 5,000 patients have been enrolled into GREAT, the largest industry-sponsored global registry of aortic stent grafts.

GREAT was started by Gore in 2010 in an effort to evaluate how their family of aortic devices perform in real-world cases and to continue their commitment to advancing patient care in the treatment of aortic diseases. Gore opened the enrollment of GREAT to include patients with all pathologies of the aorta to ensure the registry was as reflective of the real-world applications as possible.

“While clinical trials are very necessary to see if a device is appropriate and effective, often the results are not reflective of device use in daily practice,” commented Fred Weaver, MD, one of the Principal Investigators and Co-director of USC CardioVascular Thoracic Institute. “Through GREAT, we can take a look at a large number of patients with a broad set of symptoms and treatments to see how a device performs and make a better determination on proper device use in the future. This registry is truly real-world data.”

The registry tracks outcomes during treatment and posttreatment over a 10-year follow-up period. In addition to procedural and clinical outcomes, data collected includes device(s) used, disease state treated, patient demographics, and medical history to measure outcomes in various scenarios.